Compare Matson Inc (MATX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Merck & Co., Inc. — how do they compare? Matson Inc trades at $229 (market cap $6.81B), while Merck & Co., Inc. trades at $142.44 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 51.6× Matson Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Matson Inc for 23 Days and Merck & Co., Inc. for 98 Days on average.
| MATX | MRK | |
|---|---|---|
Market Cap | $6.81B | $351.28B |
Volume | 255,080 | 7,969,665 |
Sector | Industrials | Health |
52-Week High | $238.60 | $156.43 |
52-Week Low | $88.05 | $82.49 |
Typical Hold Time | 23 Days | 98 Days |
Enterprise Value | $7.41B | $398.04B |
Dividend Yield | 0.67% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $222.92, down 0.83% on the day, with technical indicators showing a neutral to bearish short-term bias. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $4.27 versus $3.79 expected, and maintains healthy profitability with a 13.41% net income margin. Recent news highlights institutional buying interest and positive analyst sentiment toward the transportation services sector.
MATX presents a compelling investment case with solid earnings growth, attractive valuation metrics (P/E of 15.37), and strong analyst support (66.7% buy ratings). Key risks include freight market volatility and competitive pressures, but the company's raised full-year outlook and dividend payments provide stability. The stock offers potential upside with Wall Street analysts projecting 27.3% price target upside.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
